Pharmacovigilance of Biologics Under Scrutiny
October 02, 2016
Regulators are tightening up on post-marketing monitoring of biological medicines to detect deficiencies caused by manufacturing problems, particularly those stemming from post-authorization changes in the manufacturing process.